Emerging studies suggest Retatrutide , a dual stimulator targeting both incretin and another hormone, may provide a significant advancement for body loss . Initial clinical trials have shown substantial losses in body tissue, conceivably surpassing existing obesity treatments. Nevertheless , additional study is required to thoroughly determine its